HIFU for Adenomyosis: What Current Evidence Can and Cannot Explain
HIFU for Adenomyosis: What Current Evidence Can and Cannot Explain
Adenomyosis is a uterine condition in which endometrial tissue is present inside the myometrium and can cause heavy bleeding, painful periods, and bulk symptoms. Interest in non‑invasive options such as high‑intensity focused ultrasound (HIFU) has grown. This article explains what published evidence says and where uncertainty remains, focusing on uterine adenomyosis (and where relevant, fibroids), how HIFU is planned and delivered, and what patients and clinicians should discuss when considering options.
Direct answer: Current evidence suggests HIFU has been studied as a treatment for adenomyosis and can be considered as one option within an individualized review. However, candidacy cannot be determined from this article, outcomes cannot be promised, and fertility cannot be predicted. Imaging, symptoms, goals, and alternatives must be assessed by a clinician to determine if HIFU can be considered in a given case.
How HIFU works and its theoretical role in adenomyosis
HIFU uses focused ultrasound energy to generate localized thermal coagulation in targeted uterine tissue without an incision. In adenomyosis, the aim is to thermally ablate troublesome areas within the myometrium. Technical planning requires detailed pre‑procedure imaging (usually MRI and/or transvaginal ultrasound) to map lesion size, depth, and relationship to the endometrium and serosa. Treatment planning also considers patient body habitus, bowel position, and prior abdominal surgery because these factors affect beam path and safety checks. A clinician assesses imaging, symptoms, and goals to determine whether HIFU can be considered in an individualized review.
What published reviews report about HIFU for adenomyosis
Systematic reviews and recent clinical series report on symptom changes and imaging after HIFU in adenomyosis, but these reports have limitations. The systematic review and meta‑analysis by Marques et al. pooled heterogeneous studies with different HIFU devices, outcome measures, and follow‑up durations. The review found that some patients experienced reductions in pain and menstrual bleeding scores and changes in lesion size on imaging, but the heterogeneity of study designs and outcome reporting limited the strength of conclusions. The more recent open‑access review by Bahutair et al. summarizes clinical series and highlights that study sizes are often small, follow‑up durations vary, and randomized comparisons are limited.
Taken together, the literature indicates that HIFU has been investigated and may be offered within research protocols or clinical practice in selected centers, but outcomes cannot be promised and long‑term comparative data are limited. Evidence has limitations such as small sample sizes, different inclusion criteria, and variable imaging endpoints, so there is uncertainty that merits individualized clinical discussion.
Who should be involved in planning HIFU?
Planning typically involves a multidisciplinary approach: a gynecologist familiar with adenomyosis, a radiologist experienced in pelvic MRI and/or ultrasound, and a HIFU treatment team. Pre‑treatment imaging is essential to assess lesion location (focal versus diffuse), depth from the serosa and endometrium, and coexisting fibroids. A clinician may discuss alternatives such as medical management, hormonal therapies, uterine‑sparing surgical options, or uterine artery embolization (UAE) depending on symptoms and reproductive goals. Because candidacy cannot be determined from this article, an individualized assessment is needed to weigh benefits, limitations, and alternative therapies.
What the evidence cannot explain: limitations and uncertainties
The current evidence cannot predict individual outcomes, fertility effects, or long‑term durability after HIFU for adenomyosis. Key limitations include:
- Heterogeneous study designs: different devices, energy settings, and technical protocols make comparisons difficult.
- Variable patient selection: studies include patients with focal adenomyosis, diffuse disease, and mixed fibroids, so a single study cannot define candidacy for all presentations.
- Outcome measures: studies use different symptom scales and imaging criteria, limiting pooled interpretation.
- Follow‑up duration: many studies have limited long‑term follow‑up to define durability.
Because of these gaps, a clinician assesses imaging, symptoms, and reproductive goals and may discuss further options or research enrollment. In short, there is uncertainty and outcomes cannot be promised by reading study results alone.
Practical considerations during assessment and treatment planning
Assessment usually includes:
- History of bleeding patterns, pain, prior therapies, and fertility goals.
- Transvaginal ultrasound to characterise uterine size and lesion features.
- MRI when available, to map depth and extent of adenomyosis and to identify fibroid coexistence; MRI can help plan beam paths and assess risks.
- Discussion of possible alternatives (medical, procedural, or surgical) with explanation that outcomes cannot be promised and fertility cannot be predicted from this article.
During a HIFU session, the treatment team monitors thermal delivery and critical structures; repeat imaging may be used to assess immediate effects. Because imaging findings can be technically challenging, a multidisciplinary review is often necessary in complex cases.
Comparison context: what HIFU does and what it does not replace
The table below summarizes conceptual differences between HIFU (non‑invasive focused ultrasound) and other uterine interventions in terms of approach and typical planning considerations. This table is for descriptive context only; it is not an endorsement and does not predict eligibility or outcomes.
| Feature | HIFU (non‑invasive) | Surgical options (laparoscopic or open) | Image‑guided embolization |
|---|---|---|---|
| Access | Trans‑abdominal ultrasound beam, no incision | Incision(s) or ports | Vascular catheter via groin or wrist |
| Imaging needs | Pre‑procedure MRI/US for planning; intra‑procedural ultrasound monitoring | Preoperative imaging; intraoperative visualisation | Angiography and cross‑sectional imaging for planning |
| Typical risks to discuss | Skin/bowel/nerve safety checks, thermal effects along beam path | Surgical wound, anaesthesia, organ injury risks | Post‑embolization pain, ischemic changes, vessel complications |
| Evidence considerations | Growing clinical series; heterogeneity limits broad generalization | Established surgical literature but requires individualized discussion | Clinical series and trials for fibroids; data on adenomyosis vary |
Clinicians discuss which approach can be considered in an individualized review; this article cannot determine suitability for any individual patient.
Frequently Asked Questions
What is adenomyosis and how is it diagnosed?
Adenomyosis is a condition where endometrial tissue is present within the uterine muscle (myometrium). Diagnosis usually combines clinical history (heavy bleeding, pain, enlarged uterus) with imaging such as transvaginal ultrasound and pelvic MRI. Imaging helps characterise focal versus diffuse patterns and assists a clinician in planning any intervention. Candidacy cannot be determined from this article; an individualized assessment is needed.
Is HIFU a surgical procedure?
HIFU is a non‑invasive focused ultrasound treatment delivered through the abdominal wall; it does not require uterine incisions. It differs from surgical and endovascular techniques and from vaginal energy devices. Whether HIFU is appropriate for a given person requires clinician review of imaging and symptoms; outcomes cannot be promised by reading study summaries.
Can HIFU preserve fertility or affect pregnancy?
Fertility effects after HIFU for adenomyosis are not settled in the literature. Published series provide limited and heterogeneous data, and fertility cannot be predicted from existing studies. Patients considering pregnancy should discuss reproductive goals with a gynecologist and fertility specialist; an individualized review is required to discuss options and uncertainties.
What are the common risks and side effects of HIFU?
Reported procedural considerations include local thermal effects, transient pain, skin sensations, and rare injury to adjacent structures if beam path safety checks are inadequate. Specific risks depend on lesion location, prior surgeries, and procedural technique. Because imaging findings can be technically challenging, a clinician assesses risks during planning and discusses alternatives; outcomes cannot be promised by this article.
How does the evidence rate HIFU compared with other treatments?
Systematic reviews note that studies of HIFU for adenomyosis are heterogeneous and often small. The literature shows changes in symptoms and imaging in some series, but heterogeneity, variable follow‑up, and differing protocols limit firm conclusions. Evidence has limitations; a clinician can discuss how HIFU compares with other options in the context of an individualized assessment.
Where can I get more individualized advice or consider HIFU?
If you are considering HIFU, arrange an evaluation where a gynecologist and imaging specialist can review your history and pelvic imaging. Candidacy cannot be determined from this article. For a consultation at Barungil OB/GYN Clinic, please use the clinic consultation link to begin an individualized review.
References
3. Bahutair et al., High‑intensity focused ultrasound in adenomyosis treatment
Medical education disclaimer: This article is for general medical education and does not provide individual medical advice. Candidacy cannot be determined from this article; outcomes cannot be promised; fertility cannot be predicted; an individualized assessment is needed.
For a consultation at Barungil OB/GYN Clinic, please visit: https://naver.me/Gct7x5NA